Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Corvus Pharma Com (CRVS)

Corvus Pharma Com (CRVS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 111,341
  • Shares Outstanding, K 62,551
  • Annual Sales, $ 0 K
  • Annual Income, $ -27,030 K
  • 60-Month Beta 1.11
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 2.62
Trade CRVS with:

Options Overview Details

View History
  • Implied Volatility 164.78% ( -6.22%)
  • Historical Volatility 49.71%
  • IV Percentile 93%
  • IV Rank 44.17%
  • IV High 288.72% on 04/24/24
  • IV Low 66.73% on 09/19/23
  • Put/Call Vol Ratio 0.00
  • Today's Volume 69
  • Volume Avg (30-Day) 43
  • Put/Call OI Ratio 0.32
  • Today's Open Interest 2,145
  • Open Int (30-Day) 2,128

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/24
See More
  • Average Estimate -0.12
  • Number of Estimates 1
  • High Estimate -0.12
  • Low Estimate -0.12
  • Prior Year -0.14
  • Growth Rate Est. (year over year) +14.29%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.7500 +4.00%
on 07/05/24
2.2200 -18.02%
on 06/13/24
-0.4000 (-18.02%)
since 06/05/24
3-Month
1.3000 +40.00%
on 04/18/24
2.3500 -22.55%
on 05/20/24
+0.0700 (+4.00%)
since 04/05/24
52-Week
1.0500 +73.33%
on 10/30/23
3.1600 -42.41%
on 07/10/23
-0.6000 (-24.79%)
since 07/05/23

Most Recent Stories

More News
Corvus: Q1 Earnings Snapshot

Corvus: Q1 Earnings Snapshot

CRVS : 1.8200 (+2.25%)
Corvus: Q4 Earnings Snapshot

Corvus: Q4 Earnings Snapshot

CRVS : 1.8200 (+2.25%)
Corvus: Q3 Earnings Snapshot

Corvus: Q3 Earnings Snapshot

CRVS : 1.8200 (+2.25%)
Corvus: Q2 Earnings Snapshot

Corvus: Q2 Earnings Snapshot

CRVS : 1.8200 (+2.25%)
Corvus: Q1 Earnings Snapshot

Corvus: Q1 Earnings Snapshot

CRVS : 1.8200 (+2.25%)
Corvus: Q4 Earnings Snapshot

Corvus: Q4 Earnings Snapshot

CRVS : 1.8200 (+2.25%)
Corvus: Q3 Earnings Snapshot

Corvus: Q3 Earnings Snapshot

CRVS : 1.8200 (+2.25%)
Corvus Pharmaceuticals Provides Business Update and Reports Second Quarter 2022 Financial Results

Prioritizing Development of CPI-818 for T Cell Lymphomas, Autoimmune and Allergic Diseases Plans to Begin Phase 2 Clinical Trial of Ciforadenant in...

CRVS : 1.8200 (+2.25%)
Corvus Pharmaceuticals Appoints Dr. James Rosenbaum Senior Vice President of Research

BURLINGAME, Calif., July 21, 2022 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Corvus or the Company) (Nasdaq: CRVS), a clinical-stage...

CRVS : 1.8200 (+2.25%)
Corvus Pharmaceuticals Provides Program Updates at R&D Symposium

Highlights new interim data from CPI-818 Phase 1/1b study in patients with relapsed T cell lymphomas Program covers scientific rationale, preclinical...

CRVS : 1.8200 (+2.25%)

Business Summary

Corvus Pharmaceuticals, Inc. is a biopharmaceutical company. It focuses on the development and commercialization of immuno-oncology therapies to harness the immune system to attack cancer cells. Its products include CPI-444, Adenosine production inhibitor, Adenosine A2B antagonist and Interleukin-2 (IL-2)-inducible...

See More

Key Turning Points

3rd Resistance Point 1.9623
2nd Resistance Point 1.9059
1st Resistance Point 1.8629
Last Price 1.8200
1st Support Level 1.7635
2nd Support Level 1.7071
3rd Support Level 1.6641

See More

52-Week High 3.1600
Fibonacci 61.8% 2.3540
Fibonacci 50% 2.1050
Fibonacci 38.2% 1.8560
Last Price 1.8200
52-Week Low 1.0500

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar